Intrinsiqq
Prothena Corporation plc logo

Prothena Corporation plc Insider Trading

PRTA

⊜ Compare
Last 12 months

Insiders sold 136K and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. The last open-market buy by an executive or director was in Mar 2017.

Net open-market
−136K
0 buys · 2 sales
Under a 10b5-1 plan
100%
of the value sold
Insiders who bought / sold
0 / 2
executives and directors
Last open-market buy
Mar 2017
Mar 9, 2017

Get an email when PRTA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Oct 22 – 23
    William P Scully
    Large holder · bought 150,000 at avg $8.15
    $1.22M
    8.6% of stake
  • Oct 13 – 14
    William P Scully
    Large holder · bought 110,000 at avg $8.36
    920K
    6.7% of stake
  • Oct 7 – 8
    William P Scully
    Large holder · bought 215,000 at avg $8.47
    $1.82M
    15% of stake
  • Oct 2
    William P Scully
    Large holder · bought 100,000 at $8.57
    857K
    7.5% of stake
  • Sep 29
    William P Scully
    Large holder · bought 162,000 at $8.68
    $1.41M
    14% of stake
  • Sep 28
    William P Scully
    Large holder · bought 103,500 at $8.60
    890K
    9.7% of stake
  • Sep 18
    William P Scully
    Large holder · bought 100,000 at $8.43
    843K
    10% of stake
  • Sep 2
    William P Scully
    Large holder · bought 27,000 at $9.47
    256K
    2.9% of stake
  • Aug 20
    William P Scully
    Large holder · bought 50,000 at $8.79
    440K
    5.6% of stake
  • Aug 7
    William P Scully
    Large holder · bought 37,500 at avg $8.62
    323K
    4.2% of stake
  • Jul 2910b5-1 plan
    Anne Evans Kingston
    Chief Strategy Officer · sold 7,662 at $8.47
    65K
    12% of stake
  • Jul 2910b5-1 plan
    Michael John Isaacs
    General Counsel & Company Sec. · sold 8,386 at $8.47
    71K
    19% of stake
  • Jun 16
    William P Scully
    Large holder · bought 20,000 at $7.90
    158K
    2.3% of stake
  • Jun 11
    William P Scully
    Large holder · bought 125,000 at $8.17
    $1.02M
    12% of stake
  • Jun 4
    William P Scully
    Large holder · bought 50,000 at $9.31
    466K
    4.9% of stake
  • Jun 2
    William P Scully
    Large holder · bought 50,000 at $9.43
    472K
    5.2% of stake
  • May 22
    William P Scully
    Large holder · bought 100,000 at $9.81
    981K
    12% of stake
  • May 2, 2025 – May 6, 2025No plan
    Ecor1 Capital, LLC
    Large holder · sold 6,279,684 at avg $8.09
    $50.8M
    54% of stake
  • Dec 18, 2024 – Jan 14, 2025
    William P Scully
    Large holder · bought 207,436 at avg $13.26
    $2.75M
    29% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch PRTA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PRTA

CompareIntrinsic value
NKTRNektar Therapeutics Inc.
$38.48+1.91%25
AQSTAquestive Therapeutics Inc.
$3.80-2.06%10
TNGXTango Therapeutics Inc.
$23.18+0.04%40
QTTBQ32 Bio Inc.
$8.97+2.40%60
SIGASiga Technologies Inc.
$3.15+1.29%20
GOSSGossamer Bio Inc.
$9.40+1.29%10
CARMCarisma Therapeutics Inc.
$0.00+100.00%60
AYTUAytu BioPharma Inc.
$1.92-0.52%48

Held by ETFs

PRTA is in 15 US ETFs. The largest of them, with PRTA's weight in each:

Spot a number that looks wrong? Check it in PRTA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PRTA

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.